胸腔镜下肺段切除与肺叶切除治疗临床Ⅰ期非小细胞肺癌疗效对比的Meta分析

doi:10.19401/j.cnki.1007-3639.2016.10.008

中国癌症杂志 ›› 2016, Vol. 26 ›› Issue (10): 854-860.doi: 10.19401/j.cnki.1007-3639.2016.10.008

胸腔镜下肺段切除与肺叶切除治疗临床Ⅰ期非小细胞肺癌疗效对比的Meta分析

郑鑫林¹，夏学阳¹，张金周¹，张建华¹，李　斌^1,2，宋铁牛¹，郭鹏鸣¹，罗越魁¹

1. 兰州大学第二医院普胸外科，甘肃兰州 730030 ；
2. 甘肃省消化系肿瘤重点实验室，甘肃兰州 730000

出版日期:2016-10-30 发布日期:2016-11-17
通信作者: 张建华　E-mail：972659434@qq.com

A Meta-analysis of video-assisted thoracic segmentectomy versus lobectomy for stage Ⅰ non-small cell lung cancer

ZHENG Xinlin¹, XIA Xueyang¹, ZHANG Jinzhou¹, ZHANG Jianhua¹, LI Bin^1,2, SONG Tieniu¹, GUO Pengming¹, LUO Yuekui¹

1.Department of General Thoracic Surgery, Second Affiliated Hospital, Lanzhou University, Lanzhou 730030, Gansu Province, China; 2.Key Laboratory of Digestive System Tumors, Lanzhou 730000, Gansu Province, China

Published:2016-10-30 Online:2016-11-17
Contact: ZHANG Jianhua E-mail: 972659434@qq.com

摘要/Abstract

摘要： 背景与目的：对于临床Ⅰ期非小细胞肺癌(non-small cell lung cancer，NSCLC)，胸腔镜下肺段切除因其对患者损伤更小而越来越受到胸外科医师的重视，但是腔镜下肺叶切除术仍被认为是标准的治疗方式。因此，系统评价胸腔镜下肺段切除与肺叶切除治疗临床Ⅰ期NSCLC的临床疗效，以期为临床决策提供借鉴。方法：计算机检索PubMed、Web of Science、EMBASE、The Cochrane Library、CNKI、CBM、VIP和万方等数据库，检索时间截至2015年7月，收集胸腔镜下肺段切除与肺叶切除治疗临床Ⅰ期NSCLC的对比研究，由2名研究员分别对纳入的研究进行数据提取和质量评价，最后采用Cochrane协作网提供的Revman 5.3软件进行Meta分析。结果：共纳入11篇回顾性临床对照研究，共计1 677例患者。Meta分析结果显示，对于临床Ⅰ期NSCLC，胸腔镜下肺段切除与肺叶切除术后总体复发率(OR=0.77，95%CI：0.48~1.21，P=0.25)、5年生存率(OR=0.77，95%CI：0.52~1.14，P=0.19)和全身并发症(OR=0.76，95%CI：0.53~1.09，P=0.13)差异均无统计学意义，但胸腔镜下肺段切除可减少术中失血量[均数差(difference in means，MD)=-41.16，95%CI：-59.46~-22.86，P<0.000 1]、缩短术后胸管引流时间(MD=-0.29，95%CI：-0.49~-0.09，P=0.005)和住院时间(MD=-0.74，95%CI：-1.44~-0.05，P=0.04)。结论：对于临床Ⅰ期NSCLC，胸腔镜下肺段切除和肺叶切除在术后总体复发率、全身并发症和5年生存率上效果相当，但是在术中失血量、术后胸管引流时间和住院时间方面胸腔镜下肺段切除效果更好，是一种可供选择的手术方式。

关键词: 肺段切除, 肺叶切除, 非小细胞肺癌, Meta分析

Abstract: Background and purpose: For stage Ⅰ non-small cell lung cancer (NSCLC), video-assisted thoracic segmentectomy is given much attention to by thoracic surgeon because of the less tissue damages. However, video-assisted thoracic lobectomy is still considered as the standard treatment in the world. Therefore, this study was to evaluate the clinical effect after video-assisted thoracic segmentectomy and lobectomy in patients with stage Ⅰ NSCLC in order to provide reference for clinical application. Methods: The comparative studies on video-assisted thoracic segmentectomy and lobectomy treating stage I NSCLC were retrieved from PubMed, Web of Science, EMBASE, the Cochrane Library, CNKI, CBM, VIP, and Wanfang Data. All data were acquired until July 2015. Literature screening according to data extraction and quality assessment was completed by two reviewers independently. Meta-analysis was conducted by RevMan 5.3 software which was offered by Cochrane network. Results: A total of 11 articles involving 1 677 patients were finally included. The results of meta-analysis indicated that: for stage Ⅰ NSCLC, compared with video-assisted thoracic lobectomy, the effect of video-assisted thoracic segmentectomy was alike in total mortality (OR=0.77, 95%CI: 0.48 to 1.21, P=0.25), 5-year mortality (OR=0.77, 95%CI: 0.52 to 1.14, P=0.19) and systemic complications (OR=0.76, 95%CI: 0.53 to 1.09, P=0.13), but could reduce blood loss [difference in means (MD)=-41.16, 95%CI: -59.46 to -22.86, P<0.000 1], chest tube duration (MD=-0.29, 95%CI: -0.49 to -0.09, P=0.005) and the length of hospital stay (MD=-0.74, 95%CI: -1.44 to -0.05, P=0.04). Conclusion: Compared with video-assisted thoracic lobectomy, video-assisted thoracic segmentectomy can significantly reduce blood loss, chest tube duration and length of hospital stay. However, the two kinds of operation methods achieved the same effects on the total mortality, 5-year mortality and systemic complications. Thoracoscopic segmentectomy may be an alternative to thoracic lobectomy.

Key words: Segmentectomy, Lobectomy, Non-small cell lung cancer, Meta-analysis

郑鑫林,夏学阳,张金周,等. 胸腔镜下肺段切除与肺叶切除治疗临床Ⅰ期非小细胞肺癌疗效对比的Meta分析[J]. 中国癌症杂志, 2016, 26(10): 854-860.

ZHENG Xinlin, XIA Xueyang, ZHANG Jinzhou, et al. A Meta-analysis of video-assisted thoracic segmentectomy versus lobectomy for stage Ⅰ non-small cell lung cancer[J]. China Oncology, 2016, 26(10): 854-860.

[1]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[2]	李海洲, 张艳炜, 许英杰, 杨　门, 张　磊, 韩京军 . miR-933调控KLF6基因影响非小细胞肺癌的作用研究[J]. 中国癌症杂志, 2021, 31(7): 581-588.
[3]	杨　佳, 刘舒媛, 王莹莹, 李盈甫, 马千里, 李　玙, 王永蓉, 李传印, 谭　芳 . 云南省汉族人群TNF-α基因多态性与非小细胞肺癌发生、发展的相关性[J]. 中国癌症杂志, 2021, 31(7): 616-628.
[4]	义维丽, 赵文成, 黄东宁, 覃　莉, 吴新天, 周　斐, 吴凤英 . PD-1单抗治疗非小细胞肺癌相关不良反应及其与疗效的相关性分析[J]. 中国癌症杂志, 2021, 31(3): 203-211.
[5]	赵媛媛, 周建英, 范　云, 王佳蕾, 黄鼎智, 李峻岭, 史美祺, 刘基巍, 姚　煜, 邬　麟, 姚文秀, 张　力 . BRAF V600突变型非小细胞肺癌的治疗进展[J]. 中国癌症杂志, 2021, 31(12): 1145-1152.
[6]	申宇嘉, 傅小龙 . 非小细胞肺癌发生、发展过程中免疫微环境变化及其临床意义[J]. 中国癌症杂志, 2021, 31(11): 1115-1125.
[7]	何　夕, 焦晓栋, 臧远胜. 肿瘤突变负荷在EGFR突变型晚期非小细胞肺癌中的临床研究进展[J]. 中国癌症杂志, 2021, 31(1): 69-75.
[8]	鲁晓腾, 许　青. 基于CT影像特征的非小细胞肺癌复发相关性因素研究[J]. 中国癌症杂志, 2020, 30(8): 636-640.
[9]	张龙富, 姚家美, 蒋冬先, 侯英勇, 张　新 . BIM联合Scribble预测晚期非小细胞肺癌化疗效果[J]. 中国癌症杂志, 2020, 30(11): 865-871.
[10]	王宝华, 沙宇婷, 何凤蝶, 吴　静. 前列腺特异性抗原对中国人群前列腺癌早期检测价值的Meta分析[J]. 中国癌症杂志, 2020, 30(11): 879-886.
[11]	方瑜佳, 周　娟, 苏春霞. 非小细胞肺癌肝转移免疫微环境及未来干预策略[J]. 中国癌症杂志, 2020, 30(10): 750-758.
[12]	李　媛. 病理学指导下的非小细胞肺癌个体化免疫治疗[J]. 中国癌症杂志, 2020, 30(10): 770-776.
[13]	杨　光, 张　昆, 王　俊 . Prospero相关同源异形盒蛋白1在非小细胞肺癌中的表达及意义[J]. 中国癌症杂志, 2020, 30(10): 791-797.
[14]	董　磊, 张仲妍 . 靶向IRF2的miR-1290对非小细胞肺癌细胞增殖、侵袭的调控作用及其机制研究[J]. 中国癌症杂志, 2020, 30(1): 32-40.
[15]	康?勋,张锡友,陈? 峰,李丹丹,董倩倩,宋清坤,钟晓松,李文斌 . CAR-T治疗B细胞淋巴瘤不良反应的Meta分析[J]. 中国癌症杂志, 2019, 29(8): 568-575.

胸腔镜下肺段切除与肺叶切除治疗临床Ⅰ期非小细胞肺癌疗效对比的Meta分析

A Meta-analysis of video-assisted thoracic segmentectomy versus lobectomy for stage Ⅰ non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价